Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

4(66.7%)

N/A

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 1(4)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06280755Recruiting

Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.

Role: collaborator

NCT04524949Phase 2Terminated

IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

Role: lead

NCT04629274Not ApplicableCompleted

In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO

Role: lead

NCT05417269Phase 1Active Not Recruiting

IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study

Role: lead

NCT04190693Phase 1Completed

IMCY-T1D-002: Long-term Follow-up Study of T1D Patients Previously Treated With IMCY-0098 or Placebo

Role: lead

NCT03272269Phase 1Completed

Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes

Role: lead

NCT02427776Phase 1Terminated

A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis

Role: lead

All 7 trials loaded